My Profile   |   Print Page   |   Contact Us   |   Sign In   |   Register
ASAP Blog
Blog Home All Blogs
Welcome to ASAP Blog, the best place to stay current regarding upcoming events, member companies, the latest trends, and leaders in the industry. Blogs are posted at least once a week; members may subscribe to receive notifications when new blogs are posted by clicking the "Subscribe" link above.

 

Search all posts for:   

 

Top tags: alliance management  alliances  collaboration  partnering  alliance  alliance managers  partners  alliance manager  partner  partnerships  ecosystem  The Rhythm of Business  governance  Jan Twombly  partnership  Strategic Alliance Magazine  Eli Lilly and Company  IoT  Vantage Partners  biopharma  Healthcare  NetApp  2015 ASAP Global Alliance Summit  ASAP BioPharma Conference  Cisco  IBM  strategy  Christine Carberry  digital transformation  innovation 

The Virtuous Cycle in Alliance Management—a Summit Spotlight Exclusive (Part 2)

Posted By Cynthia B. Hanson, Tuesday, March 5, 2019
Updated: Monday, March 4, 2019

“The alliance manager’s role is to understand the importance of timing,” advises Christine Carberry, CSAP, in Part One of ASAP Media’s interview with the seasoned alliance manager and former chief operating officer of Keryx Biopharmaceuticals (now a subsidiary of Akebia Therapeutics). Carberry, who also previously served as chair of the ASAP board of directors, will be providing a leadership spotlight plenary session, “Collaborate-Create: The Value of the Virtuous Cycle,” at the 2019 ASAP Global Alliance Summit, “Agile Partnering in Today’s Collaborative Ecosystem,” March 10-13 at the Westin Fort Lauderdale Beach Resort in Fort Lauderdale, Florida. ASAP Media’s conversation with Carberry continues below.

Carberry’s role for six months of her year working for Keryx was as co-leader of integration planning with counterpart Akebia. Early on, she realized that her role wouldn’t continue with the new organization. She is philosophical about it. “You are working on trying to have everybody see the value of the merger—employees in the companies, investors, and shareholders. Yet people know you are not going to be part of it,” she explains of the challenge. “It’s about taking the time, if you can, to explore and not think that you have to jump right back into doing exactly what you were doing. Each experience leads to another.”

Alliance mangers are seekers of “the high road” trying to rise above conflict and egos, and keeping everyone focused on the common goal.  “You’re really a navigator,” she adds. “One of the criticisms that we’ve heard is alliance managers need to think of themselves much more broadly. And think of themselves as the people always looking for a portfolio of alliances and expanding value, not just be within the confines of agreements that you have today. That’s the challenge I want to give to the audience [at the Summit] in thinking about how we can have a greater impact by making better, stronger connections between ideas and resources, creating better conditions for collaboration. Your alliance portfolio is dynamic, and I think that alliance managers can create more value by really understanding that one alliance is one piece of a company portfolio and needs to align with company strategy.”

Before her one-year stint with Keryx, Carberry spent three and a half years with FORUM Pharmaceuticals (formerly EnVivo Pharmaceuticals) and 26 years with Biogen, where she stated out in an entry-level position during a time when genetic engineering was “scary science.” Biogen was a Fortune 500 international company that brought several drugs to patients “that changed their lives,” she adds. 

Despite being in transition between jobs, Carberry has “a very full plate.” In addition to her spotlight plenary session, as chairman emerita of ASAP, she will attend the Summit board and advisory meetings and will lead a roundtable about alliance management in a crisis situation. “It’s similar to what I’ve done in other transitional periods. It allows me to increase involvement in leadership roles,” she says.

Learn about Carberry’s talk and other leadership sessions and register for the 2019 ASAP Global Alliance Summit at http://asapsummit.org. See the ASAP Media team’s comprehensive before, during, and after coverage of the 2019 Summit in Strategic Alliance publications and on the ASAP blog.  

Tags:  Akebia Therapeutics  Alliance Excellence Award  alliance manager  Christine Carberry  conflict  digital  expanding value  Keryx Biopharmaceuticals  partnership  Patheon  strategic partner  technology  Thermo Fisher 

Share |
PermalinkComments (0)
 

The Virtuous Cycle in Alliance Management—a Summit Spotlight Exclusive (Part 1)

Posted By Cynthia B. Hanson, Tuesday, March 5, 2019
Updated: Monday, March 4, 2019

“There is a time and purpose for everything. So the alliance manager’s role is to understand the importance of timing.” Thus advises Christine Carberry, CSAP, a seasoned alliance manager and former chief operating officer of Keryx Biopharmaceuticals (now a subsidiary of Akebia Therapeutics). Carberry, who also previously served as chair of the ASAP board of directors, will be providing a leadership spotlight session “Collaborate-Create: The Value of the Virtuous Cycle” at the 2019 ASAP Global Alliance Summit, “Agile Partnering in Today’s Collaborative Ecosystem,” March 10-13 at the Westin Fort Lauderdale Beach Resort in Fort Lauderdale, Florida.

A virtuous cycle connects right ideas with right resources in the right timing, she continues. “Timing is part of creating the right environment for collaboration and pulling those pieces together and then generating value,” Carberry explains. “That value often generates new ideas that just feed back into it. Growing new ideas may mean you need different kinds of resources. You may have an idea on how to improve a patient’s experience in a clinical trial. From that, you may come up with an idea that there’s a way to make that experience better using technology. Now you need different resources and skillsets to improve the patient experience in a digital way.”

Carberry’s talk is based on 30 years of management experience. Right now, she is between companies after Keryx Biopharmaceuticals and Akebia Therapeutics merged in December. The two companies are under consideration for a 2019 ASAP Alliance Excellence Award for their handling of a supply disruption where patients could not obtain a jointly manufactured drug. Access resumed after the companies teamed togetherfrom the C-level to the operational teamsto create a quick, viable solution.  

 

 “We had to navigate this partnership when Patheon merged with Fisher, and Keryx with Akebia,” Carberry explains. “Traditionally, biopharma companies treat CMOs as vendors, not as collaborators. … Applying all of the ASAP approaches and tools to the CMO I think creates a much stronger partnership, and it was demonstrated in this supply disruption situation. We needed high levels of trust with CEO engagement. It wasn’t business as usual. It was requiring people to go above and beyond,” she continues. “Agile is a good word for it. That willingness to be flexible and agile is less likely to happen if you are treating your CMO as a vendor rather than as strategic partner. “

 

See the ASAP Blog for Part Two of this interview with Christine Carberry, CSAP. Learn about Carberry’s plenary talk and other leadership sessions at the 2019 ASAP Global Alliance Summit, and register for the event, at http://asapsummit.org. See the ASAP Media team’s comprehensive before, during, and after coverage of the 2019 Summit in Strategic Alliance publications and on the ASAP blog.  

Tags:  Akebia Therapeutics  Alliance Excellence Award  alliance manager  Christine Carberry  digital  Keryx Biopharmaceuticals  partnership  Patheon  strategic partner  technology  Thermo Fisher 

Share |
PermalinkComments (0)
 

One Is Silver and the Other’s Gold: ASAP Summit Session Emphasizes Expansion Opportunities through Customer Renewal

Posted By Cynthia B. Hanson, Thursday, March 2, 2017

New customers can hold great opportunity, but don’t neglect the old accounts because they hold hidden gold that can maximize revenue through expansion. That seemed to be the main message Jeff Newton, CSAP, global strategic alliance manager at Cisco Systems, and his colleague, Manoj Bhatia, CSAP, worldwide sales and business development manager at Cisco, conveyed to the audience during their session “Accelerate Partner Sales through a Customer Success Methodology.” Then they explained how to do it. The talk took place at the recent 2017 ASAP Global Alliance Summit, “Profit, Innovation, and Value for the Part­nering Enterprise,” Feb. 28–March 2, at the San Diego Marriott Mission Valley, San Diego, California. Newton shared some thoughts from the session during an interview about his customer sales methodology.


How is the partner ecosystem changing/expanding to address new buying patterns?

From Cisco’s perspective, we are moving into lines of business where finance and marketing teams are making a lot of the decisions. It takes an ecosystem to deliver the right solution to the right customer. We need to ask how the changing ecosystem is impacting partners. We need to partner with the right people with the right technology. It’s really hard for one company to deliver the entire outcome.

Different people are making the decisions now. In the past, we would go into the IT department, find out the budget, and see how much product could be delivered. We have evolved to understanding what their pains are. To understand customers better, how can technology solve that problem? So it’s not really about selling product, it’s about selling solutions to business problems that the people in lines of business are having.

What is the role of alliance management in managing the customer?

It is good to understand what the customer is after. Ask yourself, what business problems are we solving? From an alliance management perspective, we need to put together the right ecosystem for the problem and solve the specific problem for each industry and vertical.

Please sum up your “customer success” methodology to drive an alliance to land, adopt, expand, and renew opportunities.

It’s about what the cost is to acquire a new customer. Companies spend a lot of time landing the new customer. Businesses forget to go back to that customer and find news ways to generate revenue with that customer. If you are adopting technology, you will be a lot more open. If you are helping a client build a data center, you may want to get into different lines of business to expand your sale. Also, we often don’t pay attention to sales teams, don’t focus enough on new opportunities, and we need to change our alliances to not only go after new business, but also expand together within the customer arena.

How can we measure our progress with customers?

There are some very different types of metrics we can look at. One thing I look at is the renewal rate for our support services. The industry average is about 90 percent, so if you go below 90 percent, you have an opportunity. It’s a compelling event to expand. The technology you have in your partner ecosystem will also help expand the sales and grow your footprint inside of a customer.

What are the best ways for alliance teams to lead this business transition and implement a customer success approach?

First, you really need to understand this methodology. Start looking at customers together in the same fashion. Ask how can we educate our sales teams on the ability to expand the opportunity and prepare for the renewal of the opportunity? How do we get our sales teams to think differently to engage with the customer? Look at the customer journey. Explore what they want to buy, and then evaluate it through a demonstration or something else, then the purchase, renewal opportunity, and then they can become your advocate inside the company. 

Tags:  alliance  alliance management  Cisco Systems  customer engagement  ecosystem  Jeff Newton  Manoj Bhatia  methodology  Partner Sales  technology 

Share |
PermalinkComments (0)
 

ASAP BioPharma Conference Keynoter Dr. Sam Nussbaum: ’An Industry under Siege Must Take on a Different Social Contract’

Posted By John W. DeWitt, Wednesday, October 5, 2016

A couple of weeks ago, renowned physician Dr. Samuel Nussbaum—who served as chief medical officer for Anthem through 16 years of dramatic change in the healthcare industry—took the stage at the Sept. 7-9, 2016 ASAP BioPharma Conference in Boston with a big grin, twinkling eyes, and an embrace of new ASAP Chairman Brooke Paige. Paige introduced Dr. Nussbaum and noted that speaking in Boston was a homecoming for “America’s Physician,” who trained in internal medicine at Massachusetts General and then in endocrinology at Harvard. Indeed, Nussbaum, who is now strategic consultant for EGB Advisors, paid homage to the Boston and Cambridge, Mass., area’s medical science history and still-expanding potential for academic partnerships.

“One only has to go a few blocks west of here to see where Merck began to work with Harvard; Novartis has a research center near MIT in Cambridge,” Nussbaum noted. Then he turned serious. “It’s great to be here,” he began, “but it’s also an extraordinary time in healthcare, an industry, a space, under siege. It’s no longer fully understandable to say we discover, we cure, we make health better for the world. One has to take on a different social contract … and drive collaboration.”

Nussbaum echoed Dickens’ famous description of the Elizabethan era in England.

“We live at a time which is unprecedented. It’s the best of times, because we are in an age of unprecedented advances in medical technology and human science, yet it’s the worst of times, because we have a healthcare system in the US and around the world that doesn’t provide access for everyone. The state of public health is not a focus; the quality of medical care doesn’t keep pace with the science. Looking back to halcyon days, we had a great healthcare system [in the US] and research leading to some of the most extraordinary advances in healthcare. Yet we have storm clouds on the horizon.”

Nussbaum discussed a variety of driving forces vs. restraining forces

  • Breakthrough science vs. affordability for government and private payers
  • Personalized medicine vs. reputation issues
  • Technology, big data, bioinformatics vs. value-based payment models, bundled payment
  • Patient-centered outcomes and clinical design vs. impact of consolidation

He juxtaposed several triumphs of modern medicine with what has become a key factor in recent news coverage of the pharma industry and in the run-up to 2016 US presidential election.

“Cardiac death rates dramatically reduced. Antiviral drugs transform HIV into a chronic illness vs. a killer. And screening and better drugs improve cancer survival. But there is anger, there is outrage,” over high-profile drug price increases in the US and lack of access in other places in the world. “Why are people so angry? Because they can’t afford, and as nations, we can’t afford, the cost of healthcare,” he said. “Over the last decade, the average US family wage hasn’t changed much—from $49,309 to $53,800. Why the movement to Sanders or Trump? Capitalizing on outrage.”

He further explained the context of this outrage—and why expanded coverage (in Massachusetts and across the US under Obama’s Affordable Care Act) hasn’t been the cure-all for healthcare in the US.

“Massachusetts was the first state to have universal coverage. It was done under ‘Romney Care,’ similar to ‘Obamacare,” he said. The problem? “In Massachusetts, healthcare costs went up $5.1 billion and everyone applauded that type of access. But look what happened to other essential services: public health spending down 40 percent; mental health spending down 33 percent, etc.” In other words, Nussbaum explained, “We stole from what are called the social determinants of health. We know that education and housing leads to better health and better health outcomes,” while costing less. In other words, prevention costs much less than the healthcare cure.

“More importantly,” Nussbaum continued, “we are not using our $3.2 billion wisely—30-40 percent of healthcare spending is wasted on unnecessary services, administrative costs, prices, fraud. This is what we have to contend with. That’s why it is about collaboration, why it is the focus of the Obama administration, and of private business, to introduce reforms.”

Don’t miss “Dr. Sam Nussbaum: Healing the US Healthcare System One Politician at a Time,” my colleague Genevieve Fraser’s previous blog coverage of Dr. Nussbaum’s keynote address

Tags:  Anthem  ASAP BioPharma Conference  big data  bioinformatics  Brooke Paige  bundled payment  Dr. Samuel Nussbaum  driving forces vs. restraining forces  EGB Advisors  Harvard  healthcare  Merck  MIT  Novartis  Personalized medicine  reputation issues  Technology  value-based payment models 

Share |
PermalinkComments (0)
 
For more information email us at info@strategic-alliances.org or call +1-781-562-1630